Basilea Pharmaceutica Launches Zevtera in U.S. to Combat Severe Bacterial Infections
Basilea Pharmaceutica AG has announced the commercial availability of its antibiotic Zevtera in the United States, marking a significant milestone for the company in addressing severe bacterial and fungal infections.
- Basilea Pharmaceutica Ag Allschwil
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- AI generated
2 minutes to read